The global CRISPR genome editing market is expected to grow at a CAGR of around 27% during the forecast period. The growth of this market can be attributed to the increasing demand for gene therapy and genetic engineering, which are used in various applications such as biotechnology companies and pharmaceutical companies. The increasing number of research and development activities in the field of CRISPR genome editing is also driving the growth of this market. The global CRISPR genome editing market by type is segmented into genetic engineering, gene library, human stem cells. Genetic engineering segment accounted for a major share in 2018 owing to its wide application across various industries such as biotechnology companies and pharmaceutical companies. Gene library segment is expected to grow at a higher CAGR during the forecast period owing to its use in developing new drugs with improved efficacy against diseases such as cancer, HIV/AIDS, diabetes etc, which are major drivers for this industry. Human stem cells segment accounted for a minor share in 2018 due to their high cost associated with their production process but it has been predicted that they will account for significant revenue share by 2030 owing to their potential use in regenerative medicine applications such as tissue regeneration or organ transplantation etc, which are major drivers for this industry. The global CRISPR genome editing market by application includes biotechnology companies and pharmaceutical companies while biotechnology company accounted for a major share due to its wide application across various industries such as agriculture & food processing, healthcare & medical devices etc, which are major drivers for this industry. Pharmaceutical company accounted for a minor share due to its limited application across various industries like healthcare & medical devices etc, which are not significant drivers compared with other segments within this industry.
- CRISPR genome editing is a new and promising technology that has the potential to revolutionize the way we treat genetic diseases.
- The CRISPR genome editing market is expected to grow at a CAGR of over 50% from 2018-2025, owing to its wide range of applications in various industries such as agriculture, healthcare, and others.
- The global CRISPR genome editing market is expected to reach USD 3 billion by 2025 with an estimated CAGR of over 50%.
- The global CRISPR genome editing market is driven by factors such as increasing prevalence of genetic disorders, rising demand for personalized medicine, and technological advancements in the field of gene therapy among others.
- Increasing research & development activities in this field are also driving the growth of this market.
Industry Growth Insights published a new data on “CRISPR Genome Editing Market”. The research report is titled “CRISPR Genome Editing Market research by Types (Genetic Engineering, Gene Library, Human Stem Cells, Others), By Applications (Biotechnology Companies, Pharmaceutical Companies, Others), By Players/Companies Editas Medicine, CRISPR Therapeutics, Horizon Discovery, Sigma-Aldrich, Genscript, Sangamo Biosciences, Lonza Group, Integrated DNA Technologies, New England Biolabs, Origene Technologies, Transposagen Biopharmaceuticals, Thermo Fisher Scientific, Caribou Biosciences, Precision Biosciences, Cellectis, Intellia Therapeutics”.
Scope Of The Report
Report Attributes
Report Details
Report Title
CRISPR Genome Editing Market Research Report
By Type
Genetic Engineering, Gene Library, Human Stem Cells, Others
By Application
Biotechnology Companies, Pharmaceutical Companies, Others
By Companies
Editas Medicine, CRISPR Therapeutics, Horizon Discovery, Sigma-Aldrich, Genscript, Sangamo Biosciences, Lonza Group, Integrated DNA Technologies, New England Biolabs, Origene Technologies, Transposagen Biopharmaceuticals, Thermo Fisher Scientific, Caribou Biosciences, Precision Biosciences, Cellectis, Intellia Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global CRISPR Genome Editing Market Report Segments:
The global CRISPR Genome Editing market is segmented on the basis of:
Types
Genetic Engineering, Gene Library, Human Stem Cells, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Biotechnology Companies, Pharmaceutical Companies, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Editas Medicine
- CRISPR Therapeutics
- Horizon Discovery
- Sigma-Aldrich
- Genscript
- Sangamo Biosciences
- Lonza Group
- Integrated DNA Technologies
- New England Biolabs
- Origene Technologies
- Transposagen Biopharmaceuticals
- Thermo Fisher Scientific
- Caribou Biosciences
- Precision Biosciences
- Cellectis
- Intellia Therapeutics
Highlights of The CRISPR Genome Editing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Genetic Engineering
- Gene Library
- Human Stem Cells
- Others
- By Application:
- Biotechnology Companies
- Pharmaceutical Companies
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the CRISPR Genome Editing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
CRISPR (clustered regularly interspaced short palindromic repeats) is a gene editing tool that allows scientists to make precise changes to the DNA of organisms. CRISPR can be used to correct genetic mutations, disable genes, or add new genes.
Some of the major companies in the crispr genome editing market are Editas Medicine, CRISPR Therapeutics, Horizon Discovery, Sigma-Aldrich, Genscript, Sangamo Biosciences, Lonza Group, Integrated DNA Technologies, New England Biolabs, Origene Technologies, Transposagen Biopharmaceuticals, Thermo Fisher Scientific, Caribou Biosciences, Precision Biosciences, Cellectis, Intellia Therapeutics.
The crispr genome editing market is expected to register a CAGR of 27%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. CRISPR Genome Editing Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. CRISPR Genome Editing Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. CRISPR Genome Editing Market - Supply Chain
4.5. Global CRISPR Genome Editing Market Forecast
4.5.1. CRISPR Genome Editing Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. CRISPR Genome Editing Market Size (000 Units) and Y-o-Y Growth
4.5.3. CRISPR Genome Editing Market Absolute $ Opportunity
5. Global CRISPR Genome Editing Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. CRISPR Genome Editing Market Size and Volume Forecast by Type
5.3.1. Genetic Engineering
5.3.2. Gene Library
5.3.3. Human Stem Cells
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global CRISPR Genome Editing Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. CRISPR Genome Editing Market Size and Volume Forecast by Application
6.3.1. Biotechnology Companies
6.3.2. Pharmaceutical Companies
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global CRISPR Genome Editing Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. CRISPR Genome Editing Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global CRISPR Genome Editing Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. CRISPR Genome Editing Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global CRISPR Genome Editing Demand Share Forecast, 2019-2029
9. North America CRISPR Genome Editing Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America CRISPR Genome Editing Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America CRISPR Genome Editing Market Size and Volume Forecast by Application
9.4.1. Biotechnology Companies
9.4.2. Pharmaceutical Companies
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America CRISPR Genome Editing Market Size and Volume Forecast by Type
9.7.1. Genetic Engineering
9.7.2. Gene Library
9.7.3. Human Stem Cells
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America CRISPR Genome Editing Demand Share Forecast, 2019-2029
10. Latin America CRISPR Genome Editing Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America CRISPR Genome Editing Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America CRISPR Genome Editing Market Size and Volume Forecast by Application
10.4.1. Biotechnology Companies
10.4.2. Pharmaceutical Companies
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America CRISPR Genome Editing Market Size and Volume Forecast by Type
10.7.1. Genetic Engineering
10.7.2. Gene Library
10.7.3. Human Stem Cells
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America CRISPR Genome Editing Demand Share Forecast, 2019-2029
11. Europe CRISPR Genome Editing Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe CRISPR Genome Editing Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe CRISPR Genome Editing Market Size and Volume Forecast by Application
11.4.1. Biotechnology Companies
11.4.2. Pharmaceutical Companies
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe CRISPR Genome Editing Market Size and Volume Forecast by Type
11.7.1. Genetic Engineering
11.7.2. Gene Library
11.7.3. Human Stem Cells
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe CRISPR Genome Editing Demand Share, 2019-2029
12. Asia Pacific CRISPR Genome Editing Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific CRISPR Genome Editing Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific CRISPR Genome Editing Market Size and Volume Forecast by Application
12.4.1. Biotechnology Companies
12.4.2. Pharmaceutical Companies
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific CRISPR Genome Editing Market Size and Volume Forecast by Type
12.7.1. Genetic Engineering
12.7.2. Gene Library
12.7.3. Human Stem Cells
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific CRISPR Genome Editing Demand Share, 2019-2029
13. Middle East & Africa CRISPR Genome Editing Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa CRISPR Genome Editing Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa CRISPR Genome Editing Market Size and Volume Forecast by Application
13.4.1. Biotechnology Companies
13.4.2. Pharmaceutical Companies
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa CRISPR Genome Editing Market Size and Volume Forecast by Type
13.7.1. Genetic Engineering
13.7.2. Gene Library
13.7.3. Human Stem Cells
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa CRISPR Genome Editing Demand Share, 2019-2029
14. Competition Landscape
14.1. Global CRISPR Genome Editing Market: Market Share Analysis
14.2. CRISPR Genome Editing Distributors and Customers
14.3. CRISPR Genome Editing Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Editas Medicine
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. CRISPR Therapeutics
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Horizon Discovery
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Sigma-Aldrich
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Genscript
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Sangamo Biosciences
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Lonza Group
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Integrated DNA Technologies
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. New England Biolabs
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Origene Technologies
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Transposagen Biopharmaceuticals
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Thermo Fisher Scientific
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Caribou Biosciences
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Precision Biosciences
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Cellectis
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Intellia Therapeutics
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook